Overview

* Omnicell Q2 2025 revenue rises 5% yr/yr to $291 mln, driven by connected devices

* Company exceeds guidance for non-GAAP EBITDA and EPS, reflecting strong performance

* Omnicell ( OMCL ) raises full-year 2025 guidance for total revenues, non-GAAP EBITDA, and EPS

Outlook

* Omnicell ( OMCL ) raises full-year 2025 revenue guidance to $1.130 bln - $1.160 bln

* Company expects Q3 2025 revenue between $290 mln and $300 mln

* Omnicell ( OMCL ) sees full-year non-GAAP EPS at $1.40 - $1.65

* Company forecasts Q3 non-GAAP EPS at $0.30 - $0.37

* Company forecasts Q3 non-GAAP EBITDA of $28 mln - $32 mln

Result Drivers

* CONNECTED DEVICES - Strong demand for XT Series automated dispensing cabinets and XTExtend console drove revenue growth

* NEW PRODUCTS - Introduction of MedTrack RFID Line and MedVision inventory management solution contributed to results

* REVENUE DRIVERS - Growth in connected devices, technical services, SaaS and Expert Services, and consumables revenues fueled revenue increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $291 mln

Revenue

Q2 $21 mln

Adjusted

Net

Income

Q2 Net $6 mln

Income

Q2 $38 mln

Adjusted

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Omnicell Inc ( OMCL ) is $44.00, about 32.5% above its July 30 closing price of $29.70

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)